This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Clinical Trial of CoFactor Formulations and Leucovorin Administered Intravenously in Healthy, Adult Subjects.

This study has been completed.
Information provided by:
Mast Therapeutics, Inc. Identifier:
First received: April 18, 2008
Last updated: May 27, 2009
Last verified: May 2009
The purpose of this study is to determine the safety and tolerability of CoFactor in healthy subjects.

Condition Intervention Phase
Healthy Adults Drug: CoFactor Drug: Leucovorin Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Single Dose, Within Subject, 3 Period, Pharmacokinetic Bridging Study of CoFactor Formulations and of Leucovorin Administered Intravenously in Healthy, Adult Subjects.

Further study details as provided by Mast Therapeutics, Inc.:

Primary Outcome Measures:
  • Pharmacokinetic profile of CoFactor formulations in healthy adult subjects.

Secondary Outcome Measures:
  • To measure the 5,10 methylenetetrahydrofolic acid levels after CoFactor and leucovorin administration

Estimated Enrollment: 15
Study Start Date: April 2008
Study Completion Date: May 2008
Primary Completion Date: May 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Drug: CoFactor
Other Name: ANX-510
Experimental: 2
Drug: CoFactor
Other Name: ANX-510
Active Comparator: 3
Drug: Leucovorin


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Males and Females age 18-65 inclusive at screening.
  • Subject has to agree to practice abstinence or medically accepted contraception and not to participate in sperm donation or in vitro fertilization.
  • Body Mass Index in the range of 18 to 30 kg/m2 and body weight of 45 to 95 kg.
  • Subject must be healthy as determined by the investigator on the basis of screening evaluations.
  • Subject must be nonsmoker or smoker of fewer than 10 cigarettes per day as determined by history. Must be able to abstain from smoking during the in-clinic stay.

Exclusion Criteria:

  • Presence of clinically significant illness within 21 days prior to dosing, viral or bacterial infection, or documented drug allergies that may affect subject's safety during the study.
  • Laboratory or clinical evidence suggestive of disease.
  • Clinically significant or predisposing disorder that may interfere with the absorption, distribution, metabolism and/or excretion of drugs.
  • History of drug abuse within 1 year of dosing and/or admitted alcohol abuse or history of alcohol use that may interfere with the ability to comply.
  • Pregnant, lactating, or positive pregnancy test.
  • Clinically significant electrocardiogram abnormalities.
  • History of positive test for hepatitis B or C, or HIV.
  • Positive findings of urine narcotic screen.
  • History of drug allergy.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00663481

United States, Maryland
Parexel International - Baltimore CPRU
Baltimore, Maryland, United States, 21225
Sponsors and Collaborators
Mast Therapeutics, Inc.
Principal Investigator: Ronald Goldwater, MD Parexel International - Baltimore CPRU
  More Information

Responsible Party: Jeff Stewart, MBA, ADVENTRX Pharmaceuticals, Inc. Identifier: NCT00663481     History of Changes
Other Study ID Numbers: CoFactor 510-20
Study First Received: April 18, 2008
Last Updated: May 27, 2009

Keywords provided by Mast Therapeutics, Inc.:

Additional relevant MeSH terms:
Vitamin B Complex
Growth Substances
Physiological Effects of Drugs processed this record on August 21, 2017